Jump to ContentJump to Main Navigation
Show Summary Details

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board Member: Buchner, Johannes / Lei, Ming / Ludwig, Stephan / Sies, Helmut / Turk, Boris / Wittinghofer, Alfred


SCImago Journal Rank (SJR) 2015: 1.607
Source Normalized Impact per Paper (SNIP) 2015: 0.751
Impact per Publication (IPP) 2015: 2.609

249,00 € / $374.00 / £187.00*

Online
ISSN
1437-4315
See all formats and pricing

 


 
 

Select Volume and Issue

Issues

Sub-chronic administration of the 11β-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity

Ashley Taylor1 / Nigel Irwin2 / Aine M. McKillop3 / Peter R. Flatt4 / Victor A. Gault5

1School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, Northern Ireland, UK

2School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, Northern Ireland, UK

3School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, Northern Ireland, UK

4School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, Northern Ireland, UK

5School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, Northern Ireland, UK

Corresponding author

Citation Information: Biological Chemistry. Volume 389, Issue 4, Pages 441–445, ISSN (Online) 14374315, ISSN (Print) 14316730, DOI: 10.1515/BC.2008.049, March 2008

Publication History

Received:
2007-10-26
Accepted:
2008-01-18
Published Online:
2008-03-27

Abstract

We have examined the metabolic effects of daily administration of carbenoxolone (CBX), a naturally occurring 11β-hydroxysteroid dehydrogenase (11β-HSD1) inhibitor, in mice with high fat diet-induced insulin resistance and obesity. Eight-week-old male Swiss TO mice placed on a synthetic high fat diet received daily intraperitoneal injections of either saline vehicle or CBX over a 16-day period. Daily administration of CBX had no effect on food intake, but significantly lowered body weight (1.1- to 1.2-fold) compared to saline-treated controls. Non-fasting plasma glucose levels were significantly decreased (1.6-fold) by CBX treatment on day 4 and remained lower throughout the treatment period. Circulating plasma corticosterone levels were not significantly altered by CBX treatment. Plasma glucose concentrations of CBX-treated mice were significantly reduced (1.4-fold) following an intraperitoneal glucose load compared with saline controls. Similarly, after 16-day treatment with CBX, exogenous insulin evoked a significantly greater reduction in glucose concentrations (1.4- to 1.8-fold). 11β-HSD1 gene expression was significantly down-regulated in liver, whereas glucocorticoid receptor gene expression was increased in both liver and adipose tissue following CBX treatment. The reduced body weight and improved metabolic control in mice with high fat diet-induced obesity upon daily CBX administration highlights the potential value of selective 11β-HSD1 inhibition as a new route for the treatment of type 2 diabetes and obesity.

Keywords: carbenoxolone (CBX); glucose tolerance; 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1); insulin sensitivity; obesity; type 2 diabetes

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Jongwan Kim, Eun Jung Jung, Seong-Su Moon, and Minchul Seo
Biochemical and Biophysical Research Communications, 2015
[2]
Noriko Tagawa, Sayaka Kubota, Yoshiharu Kobayashi, and Ikuo Kato
Steroids, 2015, Volume 93, Page 77
[3]
Bradford S. Hamilton, Frank Himmelsbach, Herbert Nar, Annette Schuler-Metz, Paula Krosky, Joan Guo, Rong Guo, Shi Meng, Yi Zhao, Deepak S. Lala, Linghang Zhuang, David A. Claremon, and Gerard M. McGeehan
European Journal of Pharmacology, 2015, Volume 746, Page 50
[4]
Sung Bum Park, Won Hoon Jung, Nam Sook Kang, Ji Seon Park, Gyu Hwan Bae, Hee Youn Kim, Sang Dal Rhee, Seung Kyu Kang, Jin Hee Ahn, Hye Gwang Jeong, and Ki Young Kim
European Journal of Pharmacology, 2013, Volume 721, Number 1-3, Page 70
[5]
N. Tagawa, S. Kubota, I. Kato, and Y. Kobayashi
Journal of Endocrinology, 2013, Volume 218, Number 3, Page 311
[6]
Panagiotis Anagnostis, Niki Katsiki, Fotini Adamidou, Vasilios G. Athyros, Asterios Karagiannis, Marina Kita, and Dimitri P. Mikhailidis
Metabolism, 2013, Volume 62, Number 1, Page 21
[7]
Sang Dal Rhee, Chi-Hyun Kim, Ji Seon Park, Won Hoon Jung, Sung Bum Park, Hee Youn Kim, Gyu Hwan Bae, Ta Jan Kim, and Ki Young Kim
European Journal of Pharmacology, 2012, Volume 691, Number 1-3, Page 9
[8]
C. D. Pereira, I. Azevedo, R. Monteiro, and M. J. Martins
Diabetes, Obesity and Metabolism, 2012, Volume 14, Number 10, Page 869
[9]
Nirav Dhanesha, Amit Joharapurkar, Gaurang Shah, Samadhan Kshirsagar, Vipin Dhote, Ajay Sharma, and Mukul Jain
Clinical and Experimental Pharmacology and Physiology, 2012, Volume 39, Number 1, Page 69
[10]
Nicholas Michael Morton
Molecular and Cellular Endocrinology, 2010, Volume 316, Number 2, Page 154
[11]
Ying Feng, Su-ling Huang, Wei Dou, Song Zhang, Jun-hua Chen, Yu Shen, Jian-hua Shen, and Ying Leng
British Journal of Pharmacology, 2010, Volume 161, Number 1, Page 113

Comments (0)

Please log in or register to comment.